[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200200990A1 - PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS DELTA HUMAN DELTA - Google Patents

PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS DELTA HUMAN DELTA

Info

Publication number
EA200200990A1
EA200200990A1 EA200200990A EA200200990A EA200200990A1 EA 200200990 A1 EA200200990 A1 EA 200200990A1 EA 200200990 A EA200200990 A EA 200200990A EA 200200990 A EA200200990 A EA 200200990A EA 200200990 A1 EA200200990 A1 EA 200200990A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pi3kδ
methods
inhibiting
activity
delta
Prior art date
Application number
EA200200990A
Other languages
Russian (ru)
Other versions
EA008241B1 (en
Inventor
Чанчал Садху
Кен Дик
Дженнифер Трайберг
К. Грегори Сауэлл
Эдвард А. Кесицки
Эйми Оливер
Original Assignee
Айкос Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айкос Корпорейшн filed Critical Айкос Корпорейшн
Publication of EA200200990A1 publication Critical patent/EA200200990A1/en
Publication of EA008241B1 publication Critical patent/EA008241B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)

Abstract

Раскрыты способы ингибирования активности изоформы фосфатидилинозитол-3-киназы дельта (PI3Kδ) и способы лечения заболеваний, таких как нарушения иммунитета или воспаление, в которых PI3Kδ играет роль в функции лейкоцитов. Преимущественно способы используют активные агенты, которые селективно ингибируют PI3Kδ, в то время как незначительно ингибируют активность других изоформ PI3K. Обеспечены соединения, которые ингибируют активность PI3Kδ, включая соединения, которые селективно ингибируют активность PI3Kδ. Обеспечены способы использования соединений, ингибирующих PI3Kδ, для ингибирования роста или пролиферации раковых клеток. Соответственно, изобретение обеспечивает способы применения соединений, ингибирующих PI3Kδ, для ингибирования процессов, опосредованных PI3Kδ, in vitro и in vivo.Отчет о международном поиске был опубликован 2002.03.21.Disclosed are methods for inhibiting the activity of the phosphatidylinositol-3-kinase delta (PI3Kδ) isoform and methods for treating diseases, such as immune disorders or inflammation, in which PI3Kδ plays a role in the function of white blood cells. Advantageously, the methods use active agents that selectively inhibit PI3Kδ, while slightly inhibit the activity of other PI3K isoforms. Compounds that inhibit PI3Kδ activity are provided, including compounds that selectively inhibit PI3Kδ activity. Provided methods of using compounds that inhibit PI3Kδ for inhibiting the growth or proliferation of cancer cells. Accordingly, the invention provides methods for using compounds inhibiting PI3Kδ for inhibiting PI3Kδ-mediated processes in vitro and in vivo. An international search report was published 2002.03.21.

EA200200990A 2000-04-25 2001-04-24 Inhibitors of human phosphatidyl-inositol 3-kinase delta EA008241B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19965500P 2000-04-25 2000-04-25
US23805700P 2000-10-05 2000-10-05
PCT/US2001/013315 WO2001081346A2 (en) 2000-04-25 2001-04-24 Inhibitors of human phosphatidyl-inositol 3-kinase delta

Publications (2)

Publication Number Publication Date
EA200200990A1 true EA200200990A1 (en) 2003-06-26
EA008241B1 EA008241B1 (en) 2007-04-27

Family

ID=26894992

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200990A EA008241B1 (en) 2000-04-25 2001-04-24 Inhibitors of human phosphatidyl-inositol 3-kinase delta

Country Status (27)

Country Link
US (2) US6518277B1 (en)
EP (3) EP3029041B1 (en)
JP (1) JP4642309B2 (en)
KR (1) KR100785363B1 (en)
CN (1) CN1440408B (en)
AT (1) ATE502941T1 (en)
AU (2) AU5566701A (en)
BR (1) BRPI0110371B8 (en)
CA (1) CA2406278C (en)
CY (1) CY1117672T1 (en)
DE (1) DE60144277D1 (en)
DK (3) DK1278748T3 (en)
EA (1) EA008241B1 (en)
ES (3) ES2527754T3 (en)
GE (1) GEP20084317B (en)
HK (1) HK1053308A1 (en)
HR (1) HRP20020838A2 (en)
HU (1) HU230554B1 (en)
IL (3) IL152275A0 (en)
IS (1) IS2822B (en)
MX (1) MXPA02010618A (en)
NO (2) NO329136B1 (en)
NZ (1) NZ522076A (en)
PT (3) PT1939203E (en)
RS (1) RS51458B (en)
SI (2) SI2223922T1 (en)
WO (1) WO2001081346A2 (en)

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
IL149462A0 (en) * 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US6689782B2 (en) * 2001-07-16 2004-02-10 Essential Therapeutics, Inc. Fungal efflux pump inhibitors
WO2003027276A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
EP1442132A2 (en) * 2001-10-26 2004-08-04 Novartis AG Methods for the treatment of osteoarthritis and compositions thereof
EP1444209A4 (en) * 2001-11-07 2005-02-16 Merck & Co Inc Mitotic kinesin inhibitors
EP1480980A4 (en) * 2002-02-15 2005-04-20 Cytokinetics Inc Syntheses of quinazolinones
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US6900219B2 (en) 2002-04-04 2005-05-31 Cv Therapeutics, Inc. ABCA-1 elevating compounds
WO2003094839A2 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
WO2003097053A1 (en) * 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc Compounds, compositions, and methods
JP2005538062A (en) * 2002-06-14 2005-12-15 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
EP1542703A4 (en) * 2002-07-10 2007-11-07 Massachusetts Inst Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
JP2006501201A (en) * 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
JP2005536553A (en) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
EP1558083A4 (en) * 2002-09-30 2008-04-16 Cytokinetics Inc Compounds, compositions, and methods
PT2042504E (en) 2002-09-30 2011-09-07 Bayer Schering Pharma Ag Fused azole-pyrimidine derivatives
EP1553947A4 (en) * 2002-10-21 2006-11-29 Bristol Myers Squibb Co Quinazolinones and derivatives thereof as factor xa inhibitors
EP1569653A1 (en) * 2002-12-06 2005-09-07 Warner-Lambert Company LLC Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
WO2004056820A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US7410974B2 (en) 2003-08-08 2008-08-12 Ulysses Pharmaceutical Products, Inc. Halogenated Quinazolinyl nitrofurans as antibacterial agents
EP1506967B1 (en) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
EP1699777B1 (en) * 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) * 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505933A (en) 2003-09-18 2007-03-15 コンフォーマ・セラピューティクス・コーポレイション Novel heterocyclic compounds as HSP90 inhibitors
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
WO2005067901A2 (en) * 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
BRPI0507629A (en) * 2004-02-13 2007-07-03 Banyu Pharma Co Ltd compound, receptor antagonist and h3 histamine receptor inverse agonist, prophylactic or therapeutic agent for a metabolic disease, a circulatory disease or a nervous system disease, or a pharmaceutically acceptable salt thereof
US8507484B2 (en) * 2004-02-26 2013-08-13 Kyowa Hakko Kirin Co., Ltd. Preventive and/or therapeutic agent for neutrophilic inflammatory diseases
UA85871C2 (en) * 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Dipeptidyl peptidase inhibitors
ES2425476T3 (en) 2004-04-02 2013-10-15 Prana Biotechnology Limited Neurologically active compounds
WO2005107743A1 (en) * 2004-05-06 2005-11-17 Cancer Research Technology Limited Compounds and compositions for treatment of cancer
ES2605792T3 (en) 2004-05-13 2017-03-16 Icos Corporation Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor
WO2005112935A1 (en) * 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
CN101123968A (en) * 2004-06-04 2008-02-13 艾科斯有限公司 Methods for treating mast cell disorders
PL1800693T3 (en) * 2004-08-24 2013-12-31 Chugai Pharmaceutical Co Ltd Adjuvant therapy with the use of anti-glypican 3 antibody
US20060079573A1 (en) * 2004-10-10 2006-04-13 Jakob Vinten-Johansen Methods and compositions for preventing vasospasm
JP2008520744A (en) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Anti-inflammatory pyrazolopyrimidine
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2598409A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
CA2614138A1 (en) * 2005-07-05 2007-01-11 Banyu Pharmaceutical Co., Ltd. Method for producing 4(3h)-quinazolinone derivative
KR101251157B1 (en) 2005-07-25 2013-04-10 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 B-cell reduction using cd37-specific and cd20-specific binding molecules
EP2351745A1 (en) * 2005-08-26 2011-08-03 Merck Serono S.A. Pyrazine derivatives and use as PI3K inhibitors
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
EA015169B1 (en) 2005-09-14 2011-06-30 Такеда Фармасьютикал Компани Лимитед Use of dipeptidyl peptidase inhibitors
WO2007035629A2 (en) * 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2007054556A1 (en) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (en) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazine derivatives and their use as signal transduction modulators
TWI553008B (en) 2005-12-13 2016-10-11 英塞特控股公司 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP1999108A1 (en) * 2006-03-28 2008-12-10 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
KR20090017498A (en) * 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Pi3 kinase antagonists
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
RU2487888C2 (en) * 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Single-chain multivalent binding proteins with effector function
ES2581573T3 (en) * 2006-08-08 2016-09-06 Aska Pharmaceutical Co., Ltd. Quinazoline derivative
PL2073810T3 (en) * 2006-09-13 2012-01-31 Takeda Pharmaceuticals Co Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
MX2009003673A (en) * 2006-10-04 2009-04-22 Pfizer Prod Inc Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists.
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
EP2441768A1 (en) 2006-11-13 2012-04-18 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
ES2903444T3 (en) 2007-06-13 2022-04-01 Incyte Holdings Corp Use of Janus(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile kinase inhibitor salts
UY31137A1 (en) * 2007-06-14 2009-01-05 Smithkline Beecham Corp DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THE PI3 QUINASA
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US20090131512A1 (en) * 2007-10-31 2009-05-21 Dynavax Technologies Corp. Inhibition of type I in IFN production
JP2011503193A (en) * 2007-11-13 2011-01-27 アイコス、コーポレーション Inhibitors of human phosphatidylinositol 3-kinase δ
RU2513636C2 (en) * 2008-01-04 2014-04-20 Интелликайн ЭлЭлСи Some chemical structures, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MY172151A (en) 2008-01-04 2019-11-14 Intellikine Llc Certain chemical entities, compositions and methods
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (en) 2008-03-14 2014-07-09 インテリカイン， エルエルシー Kinase inhibitors and methods of use
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
EP3009436B1 (en) 2008-07-08 2019-06-05 Intellikine, LLC Kinase inhibitors and methods of use
EP2346508B1 (en) * 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CA2975473C (en) 2008-11-13 2021-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271708A (en) * 2008-11-13 2011-12-07 新兴产品开发西雅图有限公司 CD37 immunotherapeutic combination therapies and uses thereof
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2365810A2 (en) * 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
KR20110120286A (en) 2009-02-12 2011-11-03 아스텔라스세이야쿠 가부시키가이샤 Hetero ring derivative
WO2010111432A1 (en) 2009-03-24 2010-09-30 Calistoga Pharmaceuticals Inc. Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
JP5766177B2 (en) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド Pyrimidinyl and 1,3,5-triazinylbenzimidazole sulfonamide and its use in cancer therapy
WO2010123931A1 (en) * 2009-04-20 2010-10-28 Calistoga Pharmaceuticals Inc. Methods of treatment for solid tumors
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
WO2010151735A2 (en) * 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
EA201270184A1 (en) 2009-07-21 2012-08-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи TREATMENT OF LIVER DISORDERS PI3K INHIBITORS
ES2709108T3 (en) 2009-08-17 2019-04-15 Intellikine Llc Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EP2496567B1 (en) 2009-11-05 2017-07-12 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
RS60680B1 (en) 2010-03-10 2020-09-30 Incyte Holdings Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
PL2574168T3 (en) 2010-05-21 2016-10-31 Topical formulation for a jak inhibitor
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
JP5765342B2 (en) 2010-08-10 2015-08-19 アステラス製薬株式会社 Heterocyclic compounds
ES2587657T3 (en) 2010-09-03 2016-10-26 Bayer Intellectual Property Gmbh Substituted condensed dihydropyrimidinone derivatives
US20130324561A1 (en) 2010-09-24 2013-12-05 Gilead Calistroga Llc. Atropisomers of p13k-inhibiting compounds
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UY33337A (en) 2010-10-18 2011-10-31 Respivert Ltd SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
CN103298474B (en) 2010-11-10 2016-06-29 无限药品股份有限公司 Heterocyclic compound and application thereof
AR083933A1 (en) 2010-11-19 2013-04-10 Incyte Corp PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS
BR112013017670B1 (en) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc Combination of kanase inhibitors and uses thereof
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US20140213630A1 (en) 2011-03-08 2014-07-31 Thomas Diacovo Methods and pharmaceutical compositions for treating lymphoid malignancy
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CN102731525A (en) * 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 Benzomorpholine derivative
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
LT2705029T (en) 2011-05-04 2019-02-11 Rhizen Pharmaceuticals S.A. Novel compounds as modulators of protein kinases
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TWI565709B (en) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 Heterocyclic compounds and uses thereof
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
KR20140075693A (en) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 Heterocyclic compounds and uses thereof
JP6342805B2 (en) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Substituted pyrazolo [3,4-D] pyrimidine and uses thereof
PL2834241T3 (en) 2012-03-05 2021-07-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SI3260455T1 (en) 2012-07-04 2019-07-31 Rhizen Pharmaceuticals S.A. Selective pi3k delta inhibitors
TW201414734A (en) 2012-07-10 2014-04-16 Takeda Pharmaceutical Azaindole derivatives
SG10202003090VA (en) * 2012-08-08 2020-05-28 Kbp Biosciences Co Ltd PI3K δ INHIBITOR
MX2015003874A (en) 2012-09-26 2015-12-16 Univ California Modulation of ire1.
MX2015004327A (en) * 2012-10-16 2015-06-10 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors.
WO2014072937A1 (en) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
LT2919766T (en) 2012-11-15 2021-09-27 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
KR20150082613A (en) * 2012-11-16 2015-07-15 머크 샤프 앤드 돔 코포레이션 Purine inhibitors of human phosphatidylinositol 3-kinase delta
BR112015014585A2 (en) 2012-12-21 2017-07-11 Gilead Calistoga Llc compound, pharmaceutical composition, and method of treating a human
BR112015014592A2 (en) 2012-12-21 2017-07-11 Gilead Calistoga Llc compound, pharmaceutical composition, and method for treating a human
SI2964650T1 (en) 2013-03-06 2019-05-31 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
JO3279B1 (en) 2013-03-15 2018-09-16 Respivert Ltd 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
US9227977B2 (en) 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
ES2667173T3 (en) 2013-06-14 2018-05-09 Gilead Calistoga Llc Phosphatidylinositol 3-kinase inhibitors
EP3016955B1 (en) 2013-07-02 2018-03-07 Rhizen Pharmaceuticals S.A. Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
HUE049345T2 (en) 2013-08-07 2020-09-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
EP3046563B1 (en) 2013-09-22 2019-05-29 Calitor Sciences, LLC Substituted aminopyrimidine compounds as pi3-kinase inhibitors
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2818933T3 (en) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc HDAC inhibitors in combination with pi3k inhibitors, for the treatment of non-Hodgkin lymphoma
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2017502021A (en) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー Process method for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
UY35945A (en) 2014-01-09 2015-08-31 Takeda Pharmaceutical DERIVATIVES OF AZAINDOL
PT3119397T (en) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
PT3149000T (en) * 2014-05-27 2021-07-27 Rhizen Pharmaceuticals S A Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations
JP6455995B2 (en) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド Phosphatidylinositol 3-kinase inhibitor
EA201692265A1 (en) 2014-06-13 2017-05-31 Джилид Сайэнс, Инк. PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
BR112016028876A2 (en) * 2014-06-13 2017-08-22 Gilead Sciences Inc compound, pharmaceutical composition, method for treating a disease or condition in a human, kit, and use of a compound, a salt, isomer or a pharmaceutically acceptable mixture thereof.
AU2015274635B2 (en) * 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
WO2015191745A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
MX2016017110A (en) 2014-06-24 2017-05-01 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors.
US9944639B2 (en) 2014-07-04 2018-04-17 Lupin Limited Quinolizinone derivatives as PI3K inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7096667B2 (en) 2015-07-01 2022-07-06 中外製薬株式会社 GPC3 targeted therapeutic agent administered to patients for whom GPC3 targeted therapeutic agent is effective
EP3317277B1 (en) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN111848643A (en) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 Benzoxazepine compounds and methods of use thereof
MY195002A (en) 2015-07-02 2022-12-30 Hoffmann La Roche Benzoxazepin oxazolidinone compounds and methods of use
RU2767063C2 (en) 2015-08-21 2022-03-16 МорфоСис АГ Combinations and use thereof
CN108349985A (en) 2015-09-14 2018-07-31 无限药品股份有限公司 Solid form, preparation method, the composition and its application method comprising it of isoquinolines
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
EP3272348A1 (en) 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising idelalisib
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
CA3174890A1 (en) * 2016-12-26 2018-07-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Quinazoline compound and its use as a phosphatidylinositol 3-kinase (pi3k) inhibitor
CN108239074B (en) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 Quinazoline compound, preparation method, application and pharmaceutical composition thereof
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
SG11202000523PA (en) * 2017-07-31 2020-02-27 The Trustees Of Columbia Univeristy In The City Of New York Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
AU2018318129A1 (en) 2017-08-14 2020-03-26 Mei Pharma, Inc. Combination therapy
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
MD3746429T2 (en) 2018-01-30 2022-08-31 Incyte Corp Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
WO2019178596A1 (en) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
ES2980497T3 (en) 2018-03-30 2024-10-01 Incyte Corp Treatment of hidradenitis suppurativa with JAK inhibitors
CN112601746B (en) * 2018-08-21 2022-09-16 南京明德新药研发有限公司 Pyrazolopyrimidine derivatives and their use as PI3K inhibitors
EP3870173A4 (en) 2018-10-24 2022-06-22 Vanderbilt University Wdr5 inhibitors and modulators
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CN111269231B (en) * 2018-12-04 2023-06-09 安徽中科拓苒药物科学研究有限公司 Selective PI3K delta inhibitor and application thereof
US20220249511A1 (en) * 2019-03-29 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
US20220242849A1 (en) * 2019-06-04 2022-08-04 Vanderbilt University Wdr5 inhibitors and modulators
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112830927A (en) * 2021-03-04 2021-05-25 山西科灜科技有限公司 Purine quinazolinone derivative and preparation method thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053063A (en) * 1963-05-18
DE2027645A1 (en) * 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl quinazolone (4) den vate, process for their preparation and medicinal products containing them
DE2644265C2 (en) * 1976-09-30 1983-02-10 Bayer Ag, 5090 Leverkusen Quinazoline
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
JPS55118917A (en) * 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
JPS55118918A (en) * 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
JPS6017375B2 (en) * 1979-06-20 1985-05-02 三菱電機株式会社 Manufacturing method of polyamide resin
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI951367A (en) 1994-03-28 1995-09-29 Japan Energy Corp Purine derivatives and suppressants for infectious diseases
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
JPH10507441A (en) * 1994-08-12 1998-07-21 プロ−ニューロン， インコーポレイテッド Method for treating sepsis or inflammatory disease using oxypurine nucleosides
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
WO1997041097A2 (en) * 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
HUP0000914A3 (en) * 1997-02-28 2001-09-28 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and pharmaceutical compositions containing them
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
WO1999034804A1 (en) * 1998-01-08 1999-07-15 The University Of Virginia Patent Foundation A2a adenosine receptor agonists
AU1120599A (en) * 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6046049A (en) 1999-07-19 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p110 delta expression
AU3042601A (en) 2000-01-24 2001-07-31 Thrombogenix Pty Ltd Therapeutic morpholino-substituted compounds
JP2003522174A (en) 2000-02-07 2003-07-22 ブリストル−マイヤーズ スクイブ カンパニー 3-Aminopyrazole inhibitors of cyclin-dependent kinases

Also Published As

Publication number Publication date
JP2003531209A (en) 2003-10-21
ES2788383T3 (en) 2020-10-21
KR20020093077A (en) 2002-12-12
EP3029041B1 (en) 2020-03-04
HUP0300497A3 (en) 2004-10-28
EA008241B1 (en) 2007-04-27
WO2001081346A3 (en) 2002-03-21
EP2223922A3 (en) 2011-04-27
ATE502941T1 (en) 2011-04-15
NO20100777L (en) 2002-12-10
NO20025104L (en) 2002-12-10
ES2527754T3 (en) 2015-01-29
MXPA02010618A (en) 2004-05-05
US20030195211A1 (en) 2003-10-16
PT3029041T (en) 2020-05-13
IS6585A (en) 2002-10-21
HRP20020838B1 (en) 2012-12-31
BR0110371A (en) 2003-06-17
SI3029041T1 (en) 2020-08-31
IL152275A0 (en) 2003-05-29
HU230554B1 (en) 2016-12-28
IL245146A0 (en) 2016-06-30
NO20025104D0 (en) 2002-10-24
SI2223922T1 (en) 2016-04-29
PT1939203E (en) 2015-02-04
YU80402A (en) 2005-09-19
US6518277B1 (en) 2003-02-11
CN1440408B (en) 2012-07-18
CA2406278C (en) 2012-06-05
EP1278748B1 (en) 2011-03-23
DK2223922T3 (en) 2016-06-06
NO329136B1 (en) 2010-08-30
HUP0300497A2 (en) 2003-06-28
EP1278748A2 (en) 2003-01-29
PT1278748E (en) 2011-03-31
BRPI0110371B8 (en) 2021-05-25
IS2822B (en) 2013-02-15
JP4642309B2 (en) 2011-03-02
CN1440408A (en) 2003-09-03
DK1278748T3 (en) 2011-04-18
DK1939203T3 (en) 2015-02-23
EP2223922B1 (en) 2016-03-02
AU2001255667C1 (en) 2016-06-09
ES2567260T3 (en) 2016-04-21
IL231360A (en) 2016-04-21
HK1053308A1 (en) 2003-10-17
AU5566701A (en) 2001-11-07
EP2223922A2 (en) 2010-09-01
US6800620B2 (en) 2004-10-05
BRPI0110371B1 (en) 2016-09-27
RS51458B (en) 2011-04-30
WO2001081346A2 (en) 2001-11-01
CY1117672T1 (en) 2017-05-17
IL231360A0 (en) 2014-04-30
NZ522076A (en) 2005-08-26
DE60144277D1 (en) 2011-05-05
HRP20020838A2 (en) 2004-12-31
EP3029041A1 (en) 2016-06-08
KR100785363B1 (en) 2007-12-18
GEP20084317B (en) 2008-02-25
CA2406278A1 (en) 2001-11-01
AU2001255667B2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
EA200200990A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS DELTA HUMAN DELTA
ATE493131T1 (en) QUINAZOLINE-4-ONE AS INHIBITORS OF THE HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
PT1196414E (en) PRO-PHARMACONS OF IMPDH CARBAMATE INHIBITORS
ATE424388T1 (en) MITOTIC KINESIN INHIBITORS
ATE447577T1 (en) MITOTIC KINESIN INHIBITORS
SE9800836D0 (en) New Compounds
EP2329842A3 (en) Interleukin-1 inhibitors in the treatment of diseases
EA200300248A1 (en) BICYCLOPIRASOLES, ACTIVE AS KINASE INHIBITORS, METHOD OF THEIR RECEIVING AND INCLUDING THEIR PHARMACEUTICAL COMPOSITIONS
DE60222302D1 (en) INHIBITORS OF MITOTIC KINESINE
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
ATE365550T1 (en) USE OF A PROTEIN KINASE INHIBITOR SUCH AS GENISTEIN IN THE TREATMENT OF DIABETIC RETINOPATHY
MXPA02010759A (en) (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors.
EP1939203A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
DE60209886D1 (en) TIE2 RECEPTOR KINASE INHIBITORS FOR THE TREATMENT OF ANGIOGENIC DISEASES
CY1116299T1 (en) Suspensions of the Human Phosphatidyl-Inositol-3-Kinase Delta Equilibrium Delta
DK1687642T3 (en) Screening methods for combinations of biological compounds
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU